20.500.12556/RUL-164995 Effect of combining CBD with standard breast cancer therapeutics Breast cancer is the most common malignancy in women worldwide. Sixty-five percent of breast cancers are estrogen and/or progesterone receptor positive. Estrogen receptor expression is a prognostic and predictive biomarker of response to endocrine therapy, which consists of the selective estrogen receptor modulator tamoxifen, aromatase inhibitors, and the selective estrogen receptor degrader fulvestrant. Cannabidiol is a phytocannabinoid that is emerging as a potential therapeutic agent. The aim of this study was to investigate the effect of cannabidiol on estrogen receptor-positive and estrogen receptor-negative representative breast cancer cell lines in combination with standard therapeutic agents used in clinical practice. To compare the effects of cannabidiol on breast cancer cell viability, cancer cell lines were exposed to increasing concentrations of cannabidiol. The effects of cannabidiol in combination with the endocrine therapeutics tamoxifen, fulvestrant, and the cyclin-dependent kinase inhibitor palbociclib on breast cancer cell viability were examined. We demonstrated that cannabidiol dose-dependently decreased the viability of all breast cancer cell lines independent of estrogen re- ceptor expression. The addition of cannabidiol to tamoxifen had an additive negative effect on cell viability in ER+ in estrogen receptor positive T-47D line. Cannabidiol did not attenuate the effect of standard treatment of hormone receptor-positive breast cancer with fulvestrant and palbociclib. In addition, cannabidiol did not attenuate the effect of standard treatment of triple-negative breast cancer and human epidermal growth factor receptor 2 positive breast cancer cell lines with trastuzumab and cisplatin. breast cancer cannabinoids endocrine therapy cannabidiol CBD cannabinoid receptor 1 CB1 cannabinoid receptor 2 CB2 hormone receptor HR palbociclib cisplatin trastuzumab tamoxifen fulvestrant rak dojke kanabinoidi endokrina terapija true false true Angleški jezik Slovenski jezik Članek v reviji 2024-11-20 07:10:47 2024-11-20 07:10:47 2024-11-21 13:34:39 0000-00-00 00:00:00 2022 0 0 7 str. Vol. 4, art. 100038 Jul. 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2667-3940 10.1016/j.adcanc.2022.100038 104771331 Dobovisek_Elsevier_2022.pdf Dobovisek_Elsevier_2022.pdf 1 2655AF98ED5B7EA454FCE7C8B923AB90 c89c156c00aba2662dd6dbe0aaf01a2a2529a8403b341f78e1abb30fbc156444 81771540-a706-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=195894 https://www.sciencedirect.com/science/article/pii/S2667394022000120 0 cc474af5-a705-11ef-b232-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=195893 Medicinska fakulteta Fakulteta za kemijo in kemijsko tehnologijo 0 0 0